|From: AnthonyJackson (Rep: 0)||Date: 01/18/2017 09:43|
|Forum: Neurocrine Biosciences - Msg #1113||Thread #673900131 (Rec: 0) |
|Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are trading lower by over 5% after the company announced disappointing phase II results for INGREZZA, a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor. Analysts are scrambling to find the proper price target and buy levels. Based on extensive stock chart analysis, the first major support level is at $32.75 The current stock price is $38.00. This will be a buy level for investors looking to pick up Neurocrine Biosciences on the cheap for a swing trade.|
Stock market investors buy the Neurocrine Biosciences chart
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.